Prospective Safety Study of Sintilimab Combined with XELOX Plus Bevacizumab for Preoperative Neoadjuvant Therapy of CRLM Patients with PMMR/MSS Status
Latest Information Update: 06 Dec 2024
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary) ; Sintilimab (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Adverse reactions
- 03 Dec 2024 Planned End Date changed from 30 Oct 2024 to 30 Oct 2025.
- 06 Jan 2024 Planned End Date changed from 30 Sep 2023 to 30 Oct 2024.
- 02 Aug 2023 Planned End Date changed from 30 Jun 2023 to 30 Sep 2023.